• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection

tetano

Editor, Senior Moderator
Vaccine. 2015 Apr 1. pii: S0264-410X(15)00382-5. doi: 10.1016/j.vaccine.2015.03.063. [Epub ahead of print]
[h=1]M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.[/h] Tao W[SUP]1[/SUP], Gill HS[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza virus causes seasonal epidemics and also poses a high risk for pandemics. To develop a broadly cross-protective influenza vaccine we have previously shown that a formulation consisting of the extracellular domain of M2 membrane protein (M2e) immobilized on gold nanoparticles (AuNPs) and soluble CpG as an adjuvant can elicit protective immunity against different influenza A subtypes. The vaccine formulation contains M2e that is immobilized on AuNPs, and an excess amount that is freely dissolved in solution, whose role in inducing protective immunity against virus infection is unclear. Using a mouse model, the current study shows that inclusion of excess soluble M2e antigen along with M2e immobilized on AuNPs is vital for inducing high levels of antibody response, and in providing complete protection against lethal influenza virus challenge. We also show that the vaccine induces long-lasting protection against mortality and morbidity upon lethal challenge with influenza A virus.
Copyright ? 2015. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Influenza; Long-term protection; Nanoparticle-conjugated M2e; Soluble M2e; Universal vaccine

PMID: 25842219 [PubMed - as supplied by publisher]
 
Back
Top Bottom